Skip to content Skip to navigation menu

dG (iBu)-5' CE-Phosphoramidite

dG (iBu)-5' CE-Phosphoramidite

Phosphoramidite for incorporation of an (otherwise unmodified) reverse (5’ to 3’) dG nucleobase within an oligonucleotide.
  • High performance product for use on commercial oliognucleotide synthesizers.
  • Quality ensured by full QC testing.
  • Various packaging options.
Option 1: Select a Size
Option 2: Select a Bottle Type
TBD
Add to basket to request a quote

Product information

The chemical synthesis of DNA using the phosphoramidite method proceeds in a 3’ to 5’ direction principally as a consequence of the use of building blocks activated as 3'-O-phosphoramidites. The primary 5'-OH group is significantly more reactive than the secondary 3'-OH (or 2'-OH) group, making it straightforward to protect with the DMT group leaving the 3'-OH available to form the phosphoramidite. In contrast, ‘reverse’ oligonucleotide synthesis (i.e. in a 5’ to 3’ direction) has not been utilised to nearly the same extent.
Nevertheless, there are several applications of this chemistry, most notably in nuclease resistance.
An interesting addition to the protection of antisense oligonucleotides is to modify the terminal linkages from the natural 3'-5’ to 3'-3’ and/or 5'-5’ linkages. In this way, the oligonucleotides are protected against exonuclease activity, especially 3'-exonuclease activity which is by far the most significant enzymatic degradation route, resulting in nucleosides with no toxicity concerns. This strategy has been applied by Beaucage and co-workers who have used 5'-O-phosphoramidites in the formation of oligonucleotides having alternating 3'-3’ and 5'-5’ linkages to maintain effective hybridisation. (1) A simpler approach is in fact to modify only the linkage at the 3’ terminus. (2) This is conveniently carried out and results in effective resistance with minimal disruption to hybridisation.
We provide a range of 5'-3’ “reverse” (or “inverse”) phosphoramidites and CPGs, with a variety of pore sizes and linkers consistent with our unmodified DNA and RNA CPG products. The protecting group strategies are compatible with the usual DNA and RNA chemistries.

Ref:

  1. (a) Alternating α,β-oligothymidylates with alternating (3'-3’)- and (5'-5’)-internucleotidic phosphodiester linkages as models for antisense oligodeoxyribonucleotides, M. Koga, M.F. Moore and S.L. Beaucage, J. Org. Chem., 56, 3757-3759, 1991; (b) Synthesis and physicochemical properties of alternating α,β- oligodeoxyribonucleotides with alternating (3'-3’)- and (5'-5’)-internucleotidic phosphodiester linkages, M. Koga, A. Wilk, M.F. Moore, C.L. Scremin, L. Zhou and S.L. Beaucage, J. Org. Chem., 60, 1520-1530, 1995.
  2. (a) Antisense effect of oligodeoxynucleotides with inverted terminal internucleotidic linkages: a minimal modification protecting against nucleolytic degradation, J.F.R. Ortigao, H. Rosch, H. Selter, A. Frohlich, A. Lorenz, M. Montenarh and H. Seliger, Antisense Res. & Dev., 2, 129-146, 1992; (b) Oligonucleotide analogs with terminal 3'-3'-internucleotidic and 5'-5'-internucleotidic linkages as antisense inhibitors of viral gene-expression, H. Seliger, A. Frohlich, M. Montenarh, J.F.R. Ortigao and H. Rosch, Nucleosides & Nucleotides, 10, 469-477, 1991.
Brand BioAutomation
Base dG
Modification Standard bases
Sequence Internal

Access support

Need some support with placing an order, setting up an account, or finding the right protocol?

Contact us